DeepMed Research

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Recruiting

Conditions: Retinal Vein Occlusion
Diabetic Macular Edema
Neovascular Age-related Macular Degeneration

Interventions: Drug: Faricimab

First Posted Date: 2024-06-03

Last Posted Date: 2025-05-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT06439576

Locations: 🇨🇳
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan, China
🇨🇳
Qingdao Eye Hospital of Shandong First Medical University, Qingdao, China
🇨🇳
Shanghai First People's Hospital, Shanghai, China

and more 3 locations

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

Phase 2

Recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: RO7269162

First Posted Date: 2024-05-07

Last Posted Date: 2025-05-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 245

Registration Number: NCT06402838

Locations: 🇵🇱
ProNeuro Centrum Medyczne, ?ory, Poland
🇵🇱
Podlaskie Centrum Psychogeriatrii, Bia?ystok, Poland
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 54 locations

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

Not Applicable

Recruiting

Conditions: Chlamydia Trachomatis Infection
Neisseria Gonorrhoeae Infection
Mycoplasma Genitalium Infection

Interventions: Diagnostic Test: cobas® liat CT/NG/MG nucleic acid test

First Posted Date: 2024-04-16

Last Posted Date: 2025-05-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 348

Registration Number: NCT06369220

Locations: 🇺🇸
San Francisco City Clinic, San Francisco, California, United States
🇺🇸
Planned Parenthood of Northern, Central, and Southern New Jersey, Inc., Hamilton Square, New Jersey, United States
🇺🇸
Planned Parenthood of Northern, Central and Southern New Jersey, Perth Amboy, New Jersey, United States

and more 1 locations

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Phase 2

Withdrawn

Conditions: Solid Tumors

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2024-03-26

Last Posted Date: 2024-12-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT06331598

Locations: 🇪🇸
Hospital Universitario Virgen; Servicio de Oncologia, Sevilla, Spain
🇪🇸
Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

Phase 4

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: Tumor Tissue and Blood Draw

First Posted Date: 2024-02-23

Last Posted Date: 2025-05-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 320

Registration Number: NCT06274515

Locations: 🇩🇰
Aalborg Universitetshospital, Aalborg, Denmark
🇩🇰
Sjællands Universitetshospital, Næstved, Naestved, Denmark
🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

and more 23 locations

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Placebo

First Posted Date: 2024-02-20

Last Posted Date: 2025-04-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 56

Registration Number: NCT06267001

Locations: 🇨🇳
Ningbo No.2 Hospital, Ningbo, China
🇮🇹
Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇮🇹
Azienda U.S.L. 21 - Presidio Ospedaliero S. Spirito; U.O. Di Oncologia Clinica, Casale Monferrato, Piemonte, Italy

and more 160 locations

A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Male Participants

Interventions: Drug: NXT007

First Posted Date: 2024-01-03

Last Posted Date: 2025-01-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 48

Registration Number: NCT06189508

Locations: 🇳🇿
New Zealand Clinical Research - Auckland, Auckland, New Zealand
🇳🇿
New Zealand Clinical Research - Christchurch, Christchurch, New Zealand

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Phase 3

Recruiting

Conditions: Choroidal Neovascularization Secondary to Pathologic Myopia

Interventions: Drug: Faricimab
Drug: Ranibizumab
Procedure: Sham Procedure

First Posted Date: 2023-12-19

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 280

Registration Number: NCT06176352

Locations: 🇫🇷
Chi De Creteil, Creteil, France
🇫🇷
Pole Vision Val d'Ouest, Ecully, France
🇵🇱
Klinika Okulistyczna ?Jasne Blonia? Sp. z o. o., ?ód?, Poland

and more 73 locations

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

Phase 2

Recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Genetic: delandistrogene moxeparvovec

First Posted Date: 2023-11-13

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 21

Registration Number: NCT06128564

Locations: 🇧🇪
Chr de La Citadelle, Liege, Belgium
🇫🇷
Hôpital Necker-Enfants Malades, Paris, France
🇩🇪
Universitätsklinikum Essen, Essen, Germany

and more 4 locations

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

Phase 3

Active, not recruiting

Conditions: Thyroid Eye Disease

Interventions: Drug: Satralizumab
Drug: Placebo

First Posted Date: 2023-10-30

Last Posted Date: 2025-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 127

Registration Number: NCT06106828

Locations: 🇺🇸
Retina Consultants of Texas, San Antonio, Texas, United States
🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦
Toronto Retina Institute, Toronto, Ontario, Canada

and more 38 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy